Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.44 |
| ▸ | FAP | Q12884 | 2/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389573 | 1.00 | DPP4 (0.44) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL2768507 | 1.00 | DPP4 (0.44) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL16935735 | 0.98 | DPP4 (0.46) | DPP4DPP7FAPPREPDPP8 | |
| Hydrochloric Acid SCHEMBL9653875 | 0.98 | DPP4 (0.43) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL5891316 | 0.98 | DPP4 (0.46) | DPP4DPP7FAPPREPDPP8 | |
| Hydrochloric Acid SCHEMBL4502967 | 0.98 | DPP4 (0.43) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL8612552 | 0.98 | DPP4 (0.46) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL856280 | 0.98 | DPP4 (0.46) | DPP4DPP7FAPPREPDPP8 | |
| Hydrochloric Acid SCHEMBL3947769 | 0.95 | DPP4 (0.45) | DPP4DPP7FAPPREPDPP8 | |
| SCHEMBL14656016 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | claimed |
| EP-2955233-A1 | Proteinase K inhibitors, methods and compositions therefor | Life Technologies Corporation (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-2367954-B1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | LIFE TECHNOLOGIES CORP (US) | 2015-02-18 | — | — | EP | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| CN-101917981-B | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP | 2012-11-14 | — | — | CN | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| CN-101917981-A | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP | 2010-12-15 | — | — | CN | disclosed |
| WO-2010071833-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | Life Technologies Corporation (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | DPP4 67/4885DPP7 66/4885FAP 137/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | DPP4 180/4885DPP7 259/4885FAP 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.